Pharmacokinetics and efficacy of liposomal polymyxin B in a murine pneumonia model

International Journal of Antimicrobial Agents

Volumn 42, Issue 6, 2013, Pages 559-564

  He, Jie ^a   Abdelraouf, Kamilia ^a   Ledesma, Kimberly R ^a   Chow, Diana S L ^a   Tam, Vincent H ^a  

^a UNIVERSITY OF HOUSTON   (United States)

Author keywords

Epithelial lining fluid; Multidrug resistance; Pseudomonas aeruginosa; Pulmonary

Indexed keywords

POLYMYXIN B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; BACTERIAL LOAD; BODY FLUID; CONFERENCE PAPER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG PENETRATION; EPITHELIAL LINING FLUID; EPITHELIUM; FEMALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; SURVIVAL;

EPITHELIAL LINING FLUID; MULTIDRUG RESISTANCE; PSEUDOMONAS AERUGINOSA; PULMONARY;

ADMINISTRATION, INTRAVENOUS; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL LOAD; DISEASE MODELS, ANIMAL; FEMALE; LIPOSOMES; LUNG; MICE; PNEUMONIA, BACTERIAL; POLYMYXIN B; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY MUCOSA; SERUM; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84889090433     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2013.07.009     Document Type: Conference Paper

References (32)

1. V. Balaji, S.S. Jeremiah, and P.R. Baliga Polymyxins: antimicrobial susceptibility concerns and therapeutic options Indian J Med Microbiol 29 2011 230 242
2. L.F. Chen, and D. Kaye Current use for old antibacterial agents: polymyxins, rifamycins, and aminoglycosides Infect Dis Clin North Am 23 2009 1053 1075
3. D.K. Heyland, D.J. Cook, L. Griffith, S.P. Keenan, and C. Brun-Buisson The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group Am J Respir Crit Care Med 159 1999 1249 1256
4. J.Y. Fagon, J. Chastre, A. Vuagnat, J.L. Trouillet, A. Novara, and C. Gibert Nosocomial pneumonia and mortality among patients in intensive care units JAMA 275 1996 866 869
5. C.C. Tseng, S.F. Liu, C.C. Wang, M.L. Tu, Y.H. Chung, and M.C. Lin Impact of clinical severity index, infective pathogens, and initial empiric antibiotic use on hospital mortality in patients with ventilator-associated pneumonia Am J Infect Control 40 2012 648 652
6. A. Kwa, S.K. Kasiakou, V.H. Tam, and M.E. Falagas Polymyxin B: similarities to and differences from colistin (polymyxin E) Expert Rev Anti Infect Ther 5 2007 811 821
7. Z. Yuan, and V.H. Tam Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms Expert Opin Investig Drugs 17 2008 661 668
8. J. Shoji, H. Hinoo, Y. Wakisaka, K. Koizumi, M. Mayama, and S. Matsuura Isolation of two new polymyxin group antibiotics. (Studies on antibiotics from the genus Bacillus. XX) J Antibiot (Tokyo) 30 1977 1029 1034
9. J.A. Orwa, C. Govaerts, R. Busson, E. Roets, A. Van Schepdael, and J. Hoogmartens Isolation and structural characterization of polymyxin B components J Chromatogr A 912 2001 369 373
10. J. He, K.R. Ledesma, W.Y. Lam, D.A. Figueroa, T.P. Lim, and D.S. Chow Variability of polymyxin B major components in commercial formulations Int J Antimicrob Agents 35 2010 308 310
11. A.C. Gales, R.N. Jones, and H.S. Sader Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09) J Antimicrob Chemother 66 2011 2070 2074
12. M. Castanheira, H.S. Sader, and R.N. Jones Antimicrobial susceptibility patterns of KPC-producing or CTX-M-producing Enterobacteriaceae Microb Drug Resist 16 2010 61 65
13. V.H. Tam, K.T. Chang, K. Abdelraouf, C.G. Brioso, M. Ameka, and L.A. McCaskey Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa Antimicrob Agents Chemother 54 2010 1160 1164
14. G.H. Furtado, P.A. d'Azevedo, A.F. Santos, A.C. Gales, A.C. Pignatari, and E.A. Medeiros Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant Pseudomonas aeruginosa Int J Antimicrob Agents 30 2007 315 319
15. K.P. Holloway, N.G. Rouphael, J.B. Wells, M.D. King, and H.M. Blumberg Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit Ann Pharmacother 40 2006 1939 1945
16. C.B. Teng, P.T. Koh, D.C. Lye, and B.S. Ang Continuous versus intermittent infusion of polymyxin B in the treatment of infections caused by multidrug-resistant Gram-negative bacteria Int J Antimicrob Agents 31 2008 80 82
17. T.M. Allen Liposomal drug formulations. Rationale for development and what we can expect for the future Drugs 56 1998 747 756
18. Z. Drulis-Kawa, and A. Dorotkiewicz-Jach Liposomes as delivery systems for antibiotics Int J Pharm 387 2010 187 198
19. I.A. Bakker-Woudenberg Long-circulating sterically stabilized liposomes as carriers of agents for treatment of infection or for imaging infectious foci Int J Antimicrob Agents 19 2002 299 311
20. A. Coune Liposomes as drug delivery system in the treatment of infectious diseases. Potential applications and clinical experience Infection 16 1988 141 147
21. Z. Yuan, K.R. Ledesma, R. Singh, J. Hou, R.A. Prince, and V.H. Tam Quantitative assessment of combination antimicrobial therapy against multidrug-resistant bacteria in a murine pneumonia model J Infect Dis 201 2010 889 897
22. V.H. Tam, H. Cao, K.R. Ledesma, and M. Hu In vitro potency of various polymyxin B components Antimicrob Agents Chemother 55 2011 4490 4491
23. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: seventeenth informational supplement. Document M100-S17. Wayne, PA: CLSI; 2007.
24. J. He, S. Gao, M. Hu, D.S. Chow, and V.H. Tam A validated ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of polymyxin B in mouse serum and epithelial lining fluid: application to pharmacokinetic studies J Antimicrob Chemother 68 2013 1104 1110
25. S. Kiem, and J.J. Schentag Interpretation of antibiotic concentration ratios measured in epithelial lining fluid Antimicrob Agents Chemother 52 2008 24 36
26. D. Andes, and W.A. Craig In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations Antimicrob Agents Chemother 42 1998 2375 2379
27. A.L. Kwa, T.P. Lim, J.G. Low, J. Hou, A. Kurup, and R.A. Prince Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections Diagn Microbiol Infect Dis 60 2008 163 167
28. A.P. Zavascki, L.Z. Goldani, G. Cao, S.V. Superti, L. Lutz, and A.L. Barth Pharmacokinetics of intravenous polymyxin B in critically ill patients Clin Infect Dis 47 2008 1298 1304
29. A. Omri, Z.E. Suntres, and P.N. Shek Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection Biochem Pharmacol 64 2002 1407 1413
30. M. Alipour, M. Halwani, A. Omri, and Z.E. Suntres Antimicrobial effectiveness of liposomal polymyxin B against resistant Gram-negative bacterial strains Int J Pharm 355 2008 293 298
31. T.R. Desai, G.J. Tyrrell, T. Ng, and W.H. Finlay In vitro evaluation of nebulization properties, antimicrobial activity, and regional airway surface liquid concentration of liposomal polymyxin B sulfate Pharm Res 20 2003 442 447
32. S.M. McAllister, H.O. Alpar, and M.R. Brown Antimicrobial properties of liposomal polymyxin B J Antimicrob Chemother 43 1999 203 210